Biomedical subjects

Margaret Rosenzweig

Publications and source records attributed to Margaret Rosenzweig.

2 recordsLinked to original sources

PubMed2004

Industry-sponsored weight loss programs: description, cost, and effectiveness.

PURPOSE: To describe three commercial weight loss programs (Jenny Craig, LA Weight Loss, and Weight Watchers), including efficacy data when available, and to provide clinicians with information for patient counseling. DATA SOURCES: Personal interviews, journal articles, and Web site information. CONCLUSIONS: Commercial weight loss programs provide weight loss services. Benefits are experience, planned menus, and psychological support. Limitations are cost, sales promotions that encourage on-the-spot commitment to prepaid contracts, and the cost of program food and additional vitamins. IMPLICATIONS FOR PRACTICE: Weight loss is a necessary goal for many patients. Clinicians are mandated to provide counseling regarding weight loss.

Cost-Benefit Analysis↗

PubMedDate not supplied

Hormonal therapy for breast cancer: focus on fulvestrant.

Fulvestrant, the first drug of the pure estrogen antagonists to be approved for clinical use, is a new therapeutic option for metastatic breast cancer. Fulvestrant offers a unique metastatic breast cancer treatment option because its mechanism of action is the destruction, rather than the blockade, of estrogen receptors. No known agonistic activity exists, limiting potential side effects and receptor exhaustion. The side effect profile of fulvestrant is related to its antiestrogen effect and includes gastrointestinal disturbance, urinary tract infection, and vaginitis. Suggestions for managing the side effects of fulvestrant are described, and a case study is provided as an illustrative aid in understanding the role of this new hormonal agent.

Antineoplastic Agents, Hormonal↗